185 related articles for article (PubMed ID: 29183892)
1. Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses.
Cioffi JH; Estes DJ; Florou V; Ardalan B
BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29183892
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
3. Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report.
Peng T; Ouyang Y; Tong K
Medicine (Baltimore); 2019 Jan; 98(2):e14057. PubMed ID: 30633206
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
Saneeymehri SS; Markey KR; Mahipal A
J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
[TBL] [Abstract][Full Text] [Related]
5. Rechallenging 5-Fluorouracil in a Patient With Capecitabine-Induced Ventricular Fibrillation.
Lai S; Marshall JL; Morrissey RL
Clin Colorectal Cancer; 2015 Sep; 14(3):198-201. PubMed ID: 25858685
[No Abstract] [Full Text] [Related]
6. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
[TBL] [Abstract][Full Text] [Related]
7. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
8. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
[TBL] [Abstract][Full Text] [Related]
9. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.
He Y; Liu P; Zhang Y; Deng X; Meng W; Wei M; Yang T; Wang Z; Qiu M
Trials; 2015 May; 16():238. PubMed ID: 26021722
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Karakulak UN; Aladağ E; Maharjan N; Övünç K
Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
McGavin JK; Goa KL
Drugs; 2001; 61(15):2309-26. PubMed ID: 11772141
[TBL] [Abstract][Full Text] [Related]
12. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer.
Romiti A; Onesti CE; Roberto M; Barucca V; Tomao S; D'Antonio C; Durante V; Milano A; Falcone R; Di Rocco R; Righini R; Marchetti P
Med Oncol; 2015 Mar; 32(3):54. PubMed ID: 25638466
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
14. Unilateral Capecitabine-related Hand-foot Syndrome.
Matsuda S; Koketsu H; Hayakawa M; Nagata N
Intern Med; 2015; 54(21):2779. PubMed ID: 26521911
[No Abstract] [Full Text] [Related]
15. 5-Fluorouracil Induced Hypertriglyceridemia During the Colorectal Cancer Treatment in a Patient With Multifactorial Chylomicronemia Syndrome: A Case Report.
Penesova A; Minarik P; Huckova M; Vlcek M; Szantova M; Krizanova O
Clin Ther; 2024 May; 46(5):429-432. PubMed ID: 38763818
[TBL] [Abstract][Full Text] [Related]
16. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
Brearley SG; Craven O; Saunders M; Swindell R; Molassiotis A
Eur J Cancer Care (Engl); 2010 Jul; 19(4):425-33. PubMed ID: 19708942
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
Saif MW
Clin Colorectal Cancer; 2005 Jul; 5(2):89-100. PubMed ID: 16098249
[TBL] [Abstract][Full Text] [Related]
20. [Fluoropyrimidines cardiac toxicity: 5-fluorouracil, capecitabine, compound S-1 and trifluridine/tipiracil].
Vaflard P; Ederhy S; Torregrosa C; André T; Cohen R; Lopez-Trabada D
Bull Cancer; 2018; 105(7-8):707-719. PubMed ID: 29960638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
